• Frank Grosveld, PhD

    Academy Professor of Cell Biology, Erasmus Medical Center, Rotterdam
    Founding Chief Scientific Officer, Harbour BioMed

    Dr. Grosveld is a leading molecular biologist, who along with colleagues at Erasmus University, invented Harbour BioMed's two platforms, H2L2 and HCAb, for generating fully human antibodies. He is also recognized for his research on the regulation of gene expression, including the discovery of the locus control region of globin gene. In addition, he also invented 4C (Chromosome Conformation Capture on Chips) Technology and is a co-founder of four companies, including Harbour BioMed's subsidiary, Harbour Antibodies. He is a member of the Royal Netherlands Academy of Arts and Sciences, a Fellow of the Royal Society (UK), and a Knight in the Order of the Netherlands Lion. Dr. Grosveld received his PhD Biochemistry from McGill University (Canada) and is a recipient of the Louis-Jeantet Prize for Medicine.
  • Robert Kamen, PhD

    Entrepreneur in Residence, Third Rock Ventures

    Dr. Kamen has more than 30 years of research and executive leadership experience in the pharmaceutical and biotechnology industries. Prior to Third Rock, he served as president of the Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®(adalimumab), the first approved fully human antibody product that is currently the world's top selling pharmaceutical. He also served as a member of the Abbott Pharmaceuticals Executive Management Committee. Previously, he was the President of BASF Bioresearch Corporation until its acquisition by Abbott Laboratories, and led the discovery efforts at Genetics Institute Inc. He currently serves as a director of Lycera Corp. and Opsonic Therapeutics, and as an advisor to several other biopharmaceutical companies. He holds a B.S. in Biophysics from Amherst College and a Ph.D. in Biochemistry and Molecular Biology from Harvard University.
  • Kenneth Murphy, MD, PhD

    Eugene Opie First Centennial Professor of Pathology & Immunology, Washington University School of Medicine, Investigator, Howard Hughes Medical Institute, Member, National Academy of Sciences

    Dr. Murphy bring more than 30 years of expertise and experience in the field of immunology. He is most recognized for his work into the mechanisms of immune cell lineage differentiation and known particularly for uncovering the plasticity of these processes, discovering the cytokines and transcription factors that regulate differentiation of T cells, dendritic cells and macrophages. Dr. Murphy is a HHMI investigator since 2003 and has contributed significantly to our understanding of CD4 T cell response and plasticity and developed systems to track clonal responses under physiologic settings in vitro to allow identification of cytokines, receptors and transcription factors controlling T cell fate choice into diverse phenotypes. His current work is focused on defining the developmental basis for dendritic cell diversification into the functional subsets that control induction of the various types of lymphocyte effector responses. Dr. Murphy holds a MD and PhD in Pharmacology from Johns Hopkins University School of Medicine. After a residency in Pathology and post-doctoral fellowship in molecular immunology at Washington University School of Medicine, in St. Louis, he joined the faculty there and has been with them since.
  • Robert Kramer, PhD

    CSO of SalvaRx Therapeutics; BoD, Meditope Bioscience; Chair, NeoTx SAB; Member, Servier Pharma, Aro Biotherapeutics, Crown Biosciences SAB

    Dr. Kramer's has more than 25 years of drug development experience in oncology at leading pharmaceutical companies. He has led or managed teams that advanced more than 35 drug candidates from Discovery into Development, resulting in several approved cancer drugs. He has served as Vice President and Global Head Oncology Discovery, Johnson & Johnson and previously at Bristol-Myers Squibb (BMS) as Vice President Oncology and Immunology Drug Discovery & Princeton Research Site Head. At BMS, he led and oversaw Oncology and Immunology programs that received FDA approvals for treating patients with chronic myeloid leukemia, breast cancer and melanoma. Previously, he served as Director, Oncology and Immunology Research, at Lederle-Wyeth and as an Assistant Professor at Harvard Medical School. He holds a B.S. degree in Biochemistry from Stony Brook University and a PhD in Molecular Pharmacology from the University of Vermont.
  • Peter Moesta, PhD

    Scientific and Chief CMC Advisor at Harbour BioMed, Former CEO, Adello Biologics

    Dr. Moesta brings more than 30 years of experience and leadership in biomanufacturing. He has served as Senior VP of Biologics Development and Manufacturing at Bristol-Myers Squibb, where he led the development and production of Opdivo®(nivolumab) and Yervoy®(Ipilimumab). Previously, he served as the Vice President of Biologics Manufacturing at Abbott Laboratories, where he oversaw the manufacturing process and led the CMC effort to obtain approval for Humira (adalimumab). Until its acquisition by Abbott, he served as Vice President of Biologics Process Development and Operations for BASF Research. Most recently, he served as CEO of Adello Biologics, until its acquisition in 2018 by Kashiv Pharma. Dr. Moesta holds a PhD in Biochemistry from the University of Freiburg (Germany).